Close mobile menu×
Close mobile menu

Alice Lee, MD

Board Certifications: 
Pediatric Hematology-Oncology, Pediatrics
Expertise in: 
Cancer Care
Accepting New Patients
Treats Children
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5808

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Pediatric Hematology-Oncology
  • Pediatrics

Clinical Expertise

  • Cancer Care
  • Sarcoma
  • Neuroblastoma
  • Pediatric Solid Tumors
  • Wilm's Tumor

Specialties

Education & Training

  • Boston University School of Medicine
  • Internship: St. John's Hospital, Springfield, IL
  • Residency: St. John's Hospital, Springfield, IL
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Alice Lee

Alice Lee, MD specializes in the care of children and adolescents with solid tumors, especially neuroblastoma, Wilms' tumor, and sarcomas. She also conducts research to develop and evaluate new anticancer therapies for young patients.

Dr. Lee takes a personal interest in her patients. She says, "The patients I care for are amazing. Regardless of how a child is doing during treatment, they just want to be kids. I form bonds with their families that are rich and lifelong. They come to us each day hoping their children get better, while we come to work each day hoping to advance the field with more effective therapies so more children get better. My goal is to know I've done all we can for every one of our patients, and to further therapy by developing new anticancer drugs that become a standard part of care for pediatric cancers in the future."

Dr. Lee is also intrigued by the science of pediatric oncology. In this ever-changing field, much remains to be learned, which offers her an intellectual challenge. As the institution's principal investigator for the Children's Oncology Group (COG; the nation's leading pediatric cancer research consortium), Dr. Lee and her team are evaluating new therapies and new combinations of existing therapies to identify more effective, less toxic treatments for children with cancer.

Dr. Lee is proud to be part of the team at NewYork-Presbyterian/Morgan Stanley Children's Hospital at Columbia University Medical Center, where patients have all the specialists they may need in one location, including pediatric critical care onsite if serious complications arise. Her division has leaders in every type of pediatric cancer or blood disorder.

Academic Titles

  • Assistant Professor of Pediatrics at CUMC

Administrative Positions

  • Medical Director

Hospital Affiliations

  • NewYork-Presbyterian/Morgan Stanley Children's Hospital
  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-9770
Fax:
(212) 305-5848
Primary

Research

Clinical Trials

NCT01371981 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

NCT01595048 Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - This study is ongoing, but not recruiting participants.

NCT02101853 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

NCT02166463 A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

NCT02723994 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Grants

A PHASE II STUDY OF PAZOPANIB (GW786034, NSC# 737754) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)

Dec 15 2017 - Dec 15 2022

A MULTICENTER, RANDOMIZED, PHASE 2 STUDY TO ASSESS THE FEASIBILITY, SAFETY AND EFFICACY OF OTO-104 GIVEN BY INTRATYMPANIC ADMINISTRATION IN SUBJECTS AT RISK FOR OTOTOXICITY FROM CISPLATIN CHEMOTHERAPY REGIMENS IN THE TREATMENT OF CANCER (P&S Industry Clinical Trial)

Feb 15 2017 - Feb 17 2022

A MULTI-CENTER, OPEN LABEL, NON-CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CP) OR WITH PH+ CML IN CP OR ACCEL (P&S Industry Clinical Trial)

Aug 18 2014 - Aug 31 2019

STUDY CHAIR-NIH NATIONAL CLINICAL TRIALS NETWORK (NCTN) PCR (Federal Gov)

Mar 1 2017 - Feb 28 2019

NIH NATIONAL CLINICAL TRIALS NETWORK (NCTN) PCR (Federal Gov)

Mar 1 2014 - Feb 28 2019

ADVL0921, A PHASE II STUDY OF MLN8237 (IND# 102984), A SELECTIVE AURORA A KINASE INHIBITOR IN CHILDREN WITH RECURRENT/REFRACTORY SOLID TUMORS AND LEUKEMIAS. (P&S Industry Clinical Trial)

Dec 18 2013 - Dec 31 2018

PER CASE REIMBURSEMENT AND PATIENT STUDIES (Federal Gov)

Aug 1 2014 - Sep 30 2018

SUPPORT, NIH COG PHASE 1 GRANT (Federal Gov)

Aug 1 2014 - Sep 30 2018

DIV-NB-201 (NCI:9347) - IRB: AAAK7751 (P&S Industry Clinical Trial)

Jan 23 2013 - Jan 23 2018

EVERYCHILD (APEC14B1) (Private)

Oct 26 2015 - Feb 28 2017

CANCER TRIALS SUPPORT UNIT (CTSU) PHASE II SUPPLEMENTAL PAYMENTS (N02-CM-62212) (Federal Gov)

Jan 4 2015 - Jan 3 2017

SUNCOAST CCOP RESEARCH BASE AT THE UNIVERSITY OF SOUTH FLORIDA (Federal Gov)

Jan 1 2016 - May 31 2016

MASTER SUBAWARD AGREEMENT FOR NON-INDUSTRY FUNDING SOURCES (Private)

Apr 26 2012 - Apr 25 2013

COG MASTER FOR NON-INDUSTRY STUDIES (Federal Gov)

Mar 1 2012 - Feb 28 2013

COG ARRA (Federal Gov)

Jun 1 2009 - May 31 2012

NATIONAL CHILDHOOD CANCER FOUNDATION-CHILDREN S ONCOLOGY GROUP COMMUNITY CLINICAL PROGRAM GRANT (Federal Gov)

Jun 1 2004 - May 31 2012

CHILDREN S ONCOLOGY GROUP CHAIR S GRANT (Federal Gov)

Mar 1 2008 - Feb 29 2012

CHILDREN''S ONCOLOGY GROUP CHAIR''S GRANT (Federal Gov)

Mar 1 2008 - Feb 29 2012